Photo from Erman Akkus/X
May 2, 2024, 11:41
Erman Akkus summarizes Adjuvant Aspirin in Breast Cancer
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“Adjuvant Aspirin in Breast Cancer
The Alliance A011502 randomized phase 3 trial.
Negative study, lack of benefit for invasive DFS and OS.
3020 participants
high-risk nonmetastatic breast cancer
Aspirin vs placebo
By median follow-up of 33.8 months,
invasive DFS, HR:1.27 (95% CI, 0.99-1.63; P = .06)
OS, HR: 1.19 (95% CI, 0.82-1.72).”
Visit the article website.
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19